Skip to main content

Legend Biotech Corporation (LEGN)

NASDAQ: LEGN · Delayed Price · USD
49.39
4.39 (9.76%)
At close: Dec 7, 2021 4:00 PM
50.00
0.61 (1.24%)
After-hours:Dec 7, 2021 6:18 PM EST
Market Cap7.15B
Revenue (ttm)91.58M
Net Income (ttm)-355.06M
Shares Out144.71M
EPS (ttm)-2.59
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume476,560
Open45.55
Previous Close45.00
Day's Range45.55 - 50.01
52-Week Range23.41 - 58.00
Betan/a
AnalystsStrong Buy
Price Target63.60 (+28.8%)
Earnings DateNov 15, 2021

About LEGN

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates tar...

IndustryBiotechnology
IPO DateJun 5, 2020
Employees882
Stock ExchangeNASDAQ
Ticker SymbolLEGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Legend Biotech stock is "Strong Buy." The 12-month stock price forecast is 63.60, which is an increase of 28.77% from the latest price.

Price Target
$63.60
(28.77% upside)
Analyst Consensus: Strong Buy

News

Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy C...

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech Corporation (NASDAQ: LEGN), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today the sub...

9 hours ago - Business Wire

Legend Biotech to Host Hybrid KOL Event Detailing CARTITUDE Data from the 63rd American Society of Hematology (ASH) A...

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced ...

10 hours ago - Business Wire

Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy C...

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech Corporation (NASDAQ: LEGN), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today the sub...

1 day ago - Business Wire

Legend Biotech Reports Third Quarter 2021 Financial Results and Recent Highlights

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech today reported its 2021 third quarter unaudited financial results.

3 weeks ago - Business Wire

Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel, Program and First Preclinical...

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech today announced that 12 studies were accepted for presentation at the 63rd ASH Annual Meeting and Exposition.

1 month ago - Business Wire

Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announced that the U.S. FDA has extended the Prescription Drug User Fee Act (PDUFA) target date for cilta-cel to February 28, 2022.

1 month ago - Business Wire

Legend Biotech Hits New 54-Week High

Biopharmaceutical company Legend BioTech (LEGN) hit a new 54-week high this Tuesday, up 103.4% this year.  LEGN is a multinational biopharmaceutical company primarily engaged in the discovery and develo...

1 month ago - ETF Trends

Legend Biotech to Host R&D Day on October 18, 2021

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech will host its first Research & Development Day on Monday, October 18, commencing at 10:00 a.m. (Eastern Time), at Andaz 5th Avenue.

2 months ago - Business Wire

Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapse...

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech has announced the start of a Phase 1 clinical trial in the US for an investigational treatment for relapsed/refractory T-cell lymphoma.

2 months ago - Business Wire

Legend Biotech to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech (NASDAQ: LEGN) will participate in the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on September 10 at 8:45 a.m. ET.

3 months ago - Business Wire

Legend Biotech Reports Second Quarter 2021 Financial Results and Recent Highlights

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN #earnings--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and developmen...

3 months ago - Business Wire

Legend Biotech Corporation Sponsored ADR (LEGN) Stock Jumps 7.8%: Will It Continue to Soar?

Legend Biotech Corporation Sponsored ADR (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate ...

4 months ago - Zacks Investment Research

3 Financially Solid Stock Picks for Value Investors

Benjamin Graham, the pioneer of value investing, recommended searching for stocks that have a current ratio higher than 2 and more working capital than long-term debt.

Other symbols:DECKROG
5 months ago - GuruFocus

Will This 2020 Biotech IPO Crush the Market This Year?

Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021.

Other symbols:BLUEBMYGILDJNJ
5 months ago - The Motley Fool

Legend Biotech Announces Advancement of Global Manufacturing Infrastructure

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (Legend Biotech, NASDAQ: LEGN), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell thera...

5 months ago - Business Wire

Moving Average Crossover Alert: Legend Biotech (LEGN)

Legend Biotech (LEGN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

6 months ago - Zacks Investment Research

Legend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel (cilta-cel) fo...

SOMERSET, N.J.--(BUSINESS WIRE)-- #ASCO--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel c...

6 months ago - Business Wire

Legend Biotech-Janssen's Multiple Myeloma Cell Therapy Under Review In US

Legend Biotech Corporation (NASDAQ: LEGN) has announced that the FDA accepted for priority review the marketing application submitted by Janssen Biotech Inc for ciltacabtagene autoleucel (cilta-cel) for...

6 months ago - Benzinga

U.S. Food and Drug Administration Grants BCMA CAR-T Cilta-cel Priority Review for the Treatment for Relapsed/Refracto...

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN #CARTcell--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and developmen...

6 months ago - Business Wire

Legend Biotech to Present at the Jefferies Virtual Healthcare Conference

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell th...

6 months ago - Business Wire

Are Options Traders Betting on a Big Move in Legend Biotech (LEGN) Stock?

Investors need to pay close attention to Legend Biotech (LEGN) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

Legend Biotech Reports First Quarter 2021 Financial Results and Recent Highlights

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN #Earnings--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and developmen...

6 months ago - Business Wire

Legend Biotech Reports New and Updated Data from BCMA CAR-T Program at 2021 ASCO and EHA Meetings

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN #ASCO21--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development ...

6 months ago - Business Wire

Legend Biotech Announces Submission of European Marketing Authorisation Application for BCMA CAR-T Therapy Ciltacabta...

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell th...

7 months ago - Business Wire

Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN #biotech--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development...

8 months ago - Business Wire